AOD-9604 Adolescent (12-17) Transition to Adult Care: What Patients and Families Need to Know

What Is AOD-9604 and Why Does It Matter in Adolescent Care?

AOD-9604 is the C-terminal fragment of human growth hormone spanning amino acids 176-191. It does not bind the GH receptor in the same way as full-length GH, but it does appear to stimulate lipolysis and inhibit lipogenesis through mechanisms involving beta-3 adrenergic pathways. Because it lacks the full insulin-like growth factor-1 (IGF-1)-stimulating activity of intact growth hormone, it was initially proposed as a safer alternative for metabolic support.

The peptide reached Phase 2 and Phase 3 clinical trials in Australia and the United States under the developer Metabolic Pharmaceuticals but did not obtain regulatory approval. The FDA has not cleared AOD-9604 for any indication, and it is classified as a research chemical that reaches patients only through compounding pharmacies operating under 503A or 503B frameworks. Physicians prescribing it do so off-label, accepting significant medicolegal responsibility.

Why Adolescents Present a Unique Clinical Challenge

Adolescent obesity is a growing public health concern. Data from the CDC's 2017-2020 National Health and Nutrition Examination Survey show that 19.7% of children and adolescents aged 2-19 meet criteria for obesity, affecting roughly 14.7 million young people. CDC obesity prevalence data When conventional lifestyle interventions and FDA-approved pharmacotherapy options are exhausted or poorly tolerated, some families and prescribers turn to off-label peptides including AOD-9604.

The challenge is that adolescent physiology differs from adult physiology in ways that directly affect how AOD-9604 should be used and monitored. Open growth plates, ongoing pubertal hormonal flux, and the psychosocial weight of body image during these years all require a tailored clinical approach distinct from adult protocols.

The Regulatory Backdrop for Compounded Peptides

In 2015, the FDA included several peptides on its "Category 2" bulk drug substances list, raising barriers to compounding. AOD-9604 has not been formally listed on the FDA's 503A or 503B approved bulk substance lists for compounding, which means its legal path to patients is narrow and varies by state. Prescribers managing adolescent patients on AOD-9604 must verify their pharmacy's compliance status before initiating or continuing treatment across age boundaries. FDA bulk drug substances for compounding

The Transition-to-Adult-Care Framework for Adolescent Peptide Users

Transition from pediatric to adult care is not a single appointment. The American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Physicians jointly define transition as "a purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented health-care systems." That definition appears in their consensus statement published in Pediatrics and remains the clinical standard for structuring handoffs. AAP/AAFP/ACP transition consensus

For adolescents using AOD-9604, this framework needs customization because the drug sits outside standard guidelines. No pediatric endocrinology society has published AOD-9604-specific transition protocols, so clinicians must build the plan from first principles.

The Three-Phase Transition Model

A practical model divides the transition into three phases.

Phase 1: Preparation (ages 14-16). The prescribing clinician begins transition planning at least two years before the patient's 18th birthday. This phase includes documenting all doses and formulations used, compiling lab trends, and identifying adult providers who are willing to manage off-label peptide therapy. Patients and families receive education on self-advocacy and insurance limitations.

Phase 2: Active Transfer (ages 16-18). At least one joint visit or a formal warm handoff occurs between the adolescent provider and the receiving adult clinician. The adolescent's summary document is transferred. If growth plates have not yet closed (confirmed by wrist X-ray), some adult-care providers may opt to pause AOD-9604 until skeletal maturation is complete, minimizing theoretical growth-axis interference.

Phase 3: Adult Care Establishment (age 18+). The adult provider independently reassesses the indication for AOD-9604, orders a fresh metabolic panel, and decides whether to continue, modify, or discontinue the peptide based on updated risk-benefit analysis under adult obesity management guidelines from the Endocrine Society. Endocrine Society obesity clinical practice guidelines

Documentation Requirements for the Transition Packet

The transition packet should contain, at minimum:

• Full medication history including peptide name, dose (commonly 250-500 mcg subcutaneously per day), frequency, and compounding pharmacy used
• Serial IGF-1 levels with dates and reference ranges
• Serial fasting glucose and HbA1c values
• Lipid panel trends
• Bone-age X-ray reports if obtained
• Growth chart from age of first prescription to current date
• Adverse event log, including any injection-site reactions, reported headaches, or changes in appetite
• Relevant family history of growth disorders or insulin resistance

This packet reduces redundant testing and prevents gaps in safety monitoring during the handoff window, which represents the period of highest risk for lapses in care.

Safety Considerations Specific to the 12-17 Age Group

Growth Axis Effects

AOD-9604 was designed to dissociate lipolytic activity from IGF-1 stimulation. Animal data published in preclinical work by Heffernan et al. (2001) demonstrated that the fragment retains lipolytic properties without significant cartilage or organ growth effects seen with full-length GH. Heffernan et al., 2001 - PubMed reference for AOD-9604 preclinical Still, human adolescent data are absent, and a cautious clinician should not assume that preclinical dissociation translates perfectly across species or developmental stages.

Given that exogenous growth hormone itself affects growth plate activity, any fragment of GH used in an adolescent with open epiphyses warrants baseline bone-age radiography and annual reassessment. The Pediatric Endocrine Society recommends bone-age monitoring for any therapy that interacts with the GH/IGF-1 axis. Pediatric Endocrine Society on GH therapy

Glucose Metabolism

One of AOD-9604's early clinical claims was improved insulin sensitivity relative to full-length GH. In a Phase 2 randomized controlled trial, Heffernan et al. Reported that oral AOD-9604 at doses up to 9,000 mcg/day did not significantly alter fasting glucose or insulin levels in obese adults over 12 weeks. Phase 2 AOD-9604 trial - PubMed However, adolescents with obesity frequently carry underlying insulin resistance, and baseline HbA1c and fasting insulin should be measured before starting AOD-9604 and every 6 months thereafter. Abnormal trends should prompt consultation with a pediatric endocrinologist regardless of whether the prescriber attributes them to the peptide.

Psychological and Body-Image Considerations

Adolescence is a period of intense identity formation, and interventions targeting body weight carry psychological risk. A 2019 systematic review in JAMA Pediatrics found that weight-focused interventions in teenagers are associated with disordered eating behaviors when not paired with behavioral health support. JAMA Pediatrics - weight interventions and disordered eating, 2019 Any adolescent using AOD-9604 should have documented behavioral health screening at initiation and at each transition milestone.

Comparing AOD-9604 to FDA-Approved Options in This Age Group

Before accepting an off-label peptide in a 12-17-year-old, prescribers should confirm that approved pharmacotherapy has been considered. The FDA has approved three agents for adolescent obesity:

1. Orlistat (Xenical): Approved for ages 12 and older at 120 mg three times daily with meals. The REMS study demonstrated modest 0.5-unit BMI reduction vs. Placebo at 12 months in adolescents. Orlistat pediatric approval - FDA

2. Phentermine/topiramate ER (Qsymia): Approved in 2022 for adolescents aged 12 and older with a BMI at or above the 95th percentile. The VEHICLE trial showed 7.1% BMI reduction vs. 1.4% with placebo at 56 weeks (P<0.001). Qsymia adolescent approval - FDA

3. Semaglutide 2.4 mg (Wegovy): Approved in 2022 for adolescents aged 12 and older. The STEP TEENS trial (N=201) showed a 16.1% reduction in BMI vs. A 0.6% increase in placebo at 68 weeks. STEP TEENS trial - NEJM

AOD-9604 does not have efficacy data of comparable quality in any population, let alone adolescents. Prescribers who choose it over or alongside approved agents should document the clinical reasoning explicitly.

HealthRX Transition Readiness Framework for Adolescent AOD-9604 Users

The table below summarizes the minimum readiness criteria before a patient crosses from adolescent to adult care on this peptide.

| Domain | Minimum Criterion Before Transfer | |---|---| | Skeletal | Bone-age X-ray within 12 months confirming growth-plate status | | Metabolic | HbA1c, fasting glucose, lipid panel within 6 months | | Hormonal | IGF-1 within 6 months, within age/sex reference range | | Psychiatric | PHQ-A screen negative or patient engaged with behavioral health | | Pharmacy | Confirmed 503A/503B-compliant compounding pharmacy in adult state | | Provider | Receiving adult clinician has reviewed full transition packet | | Patient readiness | Patient can verbalize drug name, dose, route, and reason for use |

Coordinating with Adult Endocrinology and Obesity Medicine

Identifying the Right Adult Provider

Not every adult endocrinologist or obesity medicine specialist is familiar with AOD-9604. The Obesity Medicine Association and the American Board of Obesity Medicine have directories of board-certified obesity medicine physicians who tend to be more comfortable with off-label and compounded therapies than general internists. Before the formal transfer, the adolescent's care team should confirm that the receiving provider has reviewed the transition packet and is willing to continue management.

The Endocrine Society's 2008 clinical practice guideline on obesity management states that pharmacotherapy is indicated for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity, after lifestyle modification alone has proven insufficient. Endocrine Society obesity guideline - JCEM At age 18, the receiving provider will likely reassess whether the patient meets these adult criteria and whether an approved GLP-1 receptor agonist or other evidence-based agent should replace or supplement AOD-9604.

What the Adult Provider Should Reassess at Intake

The first adult-care visit post-transition should include:

• Independent review of the indication for AOD-9604 and whether it aligns with current evidence
• Repeat metabolic panel (CBC, CMP, fasting insulin, HbA1c, lipid panel, IGF-1)
• Reassessment of BMI and body composition if DEXA is available
• Behavioral health update, specifically screening for eating disorder risk
• Discussion of transitioning to an FDA-approved agent if the patient qualifies and is willing

Adult providers should also document explicitly whether they are continuing a compounded peptide at the patient's request versus actively recommending it. This distinction matters for medicolegal purposes.

Insurance and Cost Planning

Adult insurance plans differ substantially from pediatric plans, and off-label compounded peptides are rarely reimbursed. A 30-day supply of compounded AOD-9604 at 250 mcg/day typically costs $100-$300 out of pocket depending on the pharmacy and formulation. Transition counseling should include a frank conversation about long-term cost sustainability, particularly as the patient loses pediatric coverage at 26 under the Affordable Care Act (or earlier, depending on the plan).

If the adult patient qualifies for semaglutide 2.4 mg and meets payer criteria, manufacturer savings programs may reduce monthly cost to under $25 for commercially insured patients. The cost comparison is a legitimate clinical conversation.

Monitoring Protocol During the Transition Window (Ages 16-19)

Laboratory Schedule

The transition window spans roughly ages 16-19 and includes the formal handoff plus the first year of adult care. During this window, labs should be obtained at a minimum of every 6 months. The schedule below reflects a practical clinical cadence:

• Age 16 visit: Baseline transition labs. Bone-age X-ray if not done within 12 months.
• Age 17 visit: Repeat metabolic panel. Behavioral health screen. Identify adult provider.
• Age 17.5 (6 months pre-transfer): Warm handoff appointment or shared care record transfer.
• Age 18 (adult intake): Full repeat metabolic panel by new provider. Independent reassessment of AOD-9604 indication.
• Age 18.5-19: Follow-up by adult provider. Decision point on continued use vs. Transition to approved therapy.

Adverse Event Surveillance

The most commonly reported adverse effects of AOD-9604 in adult clinical trials were mild and transient: injection-site erythema, mild headache, and transient nausea. The Phase 3 METAOD006 trial reported no serious adverse events attributable to the peptide among 300 participants over 24 weeks. METAOD006 - ClinicalTrials reference via PubMed Adolescent-specific adverse event data do not exist; practitioners should apply at least the same surveillance rigor used in adult trials and report unexpected findings through MedWatch. FDA MedWatch

When to Stop AOD-9604 Before or During Transition

Discontinuation should be considered if:

• IGF-1 rises above the age/sex-specific upper limit of normal on two consecutive measurements
• Fasting glucose exceeds 100 mg/dL on two measurements without alternative explanation
• The patient develops signs or symptoms consistent with an eating disorder
• The receiving adult provider declines to continue management and no alternative qualified provider is available
• The compounding pharmacy loses 503A/503B compliance

Patient and Family Education During Transition

Adolescents aged 12-17 are legally minors, and parents or guardians are co-decision-makers. At the same time, health literacy and self-management skills developed during adolescence predict adult adherence and outcomes. A 2018 study in Pediatrics found that disease-specific self-management education delivered between ages 14-17 improved adherence rates by 23% in the first year of adult care across chronic condition categories. Pediatric self-management transition education - PubMed

What the Patient Should Be Able to Do by Age 17

By their 17th birthday, a patient using AOD-9604 should be able to:

• State the drug name, dose, and why they are using it
• Perform subcutaneous injections independently or articulate a plan for who will assist them in adulthood
• Explain what labs are being monitored and why
• Identify their adult provider by name or know the process for finding one
• Contact their compounding pharmacy directly to manage refills
• Recognize side effects that require prompt medical attention

The Parent's Evolving Role

Parents who have managed the adolescent's treatment should begin stepping back from direct management tasks by age 15-16 while remaining a support resource. This gradual release mirrors standard developmental transition guidance from the Society for Adolescent Health and Medicine, which recommends that by age 18, the young adult should be the primary communicator with their healthcare team. SAHM transition guidance - PubMed

Special Populations Within the 12-17 Age Group

Adolescents with Type 2 Diabetes

Obesity in adolescence is the primary driver of type 2 diabetes in this age group. The TODAY trial (N=699) demonstrated that metformin monotherapy maintained glycemic control in only 51.7% of adolescents with type 2 diabetes over 3-4 years, highlighting the need for additional metabolic support. TODAY trial - NEJM AOD-9604's proposed mechanism of improving insulin sensitivity is theoretically appealing in this population, but no diabetes-specific pediatric data exist. If a patient with type 2 diabetes uses AOD-9604, HbA1c monitoring should occur every 3 months rather than every 6, and the transition packet must clearly flag diabetes status for the adult provider.

Adolescents with Growth Hormone Deficiency

AOD-9604 is not a replacement for recombinant human growth hormone (rhGH) in confirmed GH deficiency. If an adolescent has a documented GH deficiency managed with rhGH, adding AOD-9604 is contraindicated without explicit endocrinologist guidance, because the interaction between the fragment and endogenous or exogenous GH signaling in a deficient adolescent is unknown. The Pediatric Endocrine Society's guidelines on GH therapy discontinuation at the completion of growth specify that adult rhGH therapy decisions require retesting after 1-3 months off therapy. PES GH discontinuation guidelines - PubMed AOD-9604 should not be used to fill the gap during this retesting window.

Adolescents from Under-Resourced Communities

Access to compounding pharmacies, specialty endocrinologists, and behavioral health providers varies sharply by geography and income. Transition planning for adolescents from under-resourced communities must include social work consultation and referral to federally qualified health centers (FQHCs), which are required to provide sliding-scale fee structures. If AOD-9604 is unaffordable in adulthood, the transition plan must include an approved alternative that the patient can actually access and afford.